

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Koen VANDENBROECK; Iraide ALLOZA

Application No.: Not Yet Assigned
(International Application No. PCT/IB2003/006404)

Filed: Herewith
(International Application: 8 December 2003 (08.12.2003))

For: RECOMBINANT CELL LINE

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The present application is a 371 of PCT/IB2003/006404. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate is a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. It is believed that copies of the references have been or will be forwarded by the International Search Authority. Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EV 320480627 US
Date of Deposit: 06 JUNE 2005

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Signature of person mailing page:
Leola P. Goodman
Type or print name of person

JC09 Re [REDACTED] PCT/PTO 36 JUN 2005,

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

This Information disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,
KOEN VANDENBROECK *et al.*

BY


DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 08830-0344US1	SERIAL NO. Not Yet Known
INFORMATION DISCLOSURE STATEMENT		International No.: PCT/IB2003/006404			
		APPLICANT: Koen Vandenbroeck et al.			
		FILING DATE Herewith	GROUP 1636 Not Yet Known		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/C.H./	AA	5,972,986	10/26/1999	Seibert et al.	514	406	
/C.H./	AB	2002/0119193	8/29/2002	Le et al.	424	465	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <u>YES</u> <u>NO</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/C.H./	AC	Dunlop et al., "Inducible Expression And Pharmacology Of The Human Excitatory Amino Acid Transporter 2 Subtype Of L-Glutamate Transporter", <i>British Journal Of Pharmacology</i> 128:1485-1490 (1999)
/C.H./	AD	Graham et al., "Ecdysone-Controlled Expression Of Transgenes", <i>Expert Opinion On Biological Therapy</i> 2:525-535 (2002)
/C.H./	AE	Martens et al., "Protein Disulfide Isomerase-Mediated Cell-Free Assembly Of Recombinant Interleukin-12 p40 Homodimers", <i>European Journal Of Biochemistry</i> 267:6679-6683 (2000)
/C.H./	AF	Nagy et al., "Inducible Expression And Pharmacology Of Recombinant NMDA Receptors, Composed Of Rat NR1/NR2B Subunits", <i>Neurochemistry International</i> 43:19-29 (2003)
/C.H./	AG	Davies et al., "Clinical Pharmacokinetics And Pharmacodynamics Of Celecoxib", <i>Clinical Pharmacokinetics</i> 38:225-242 (2000)
/C.H./	AH	Chen et al., "Selective Inhibition Of COX-2 Is Beneficial To Mice Infected Intranasally With VSV" <i>Prostaglandins And Other Lipid Mediators</i> 67:143-155 (2002)
/C.H./	AI	Cuzzocrea et al., "Celecoxib, A Selective Cyclo-Oxygenase-2 Inhibitor Reduces The Severity Of Experimental Colitis Induced By Dinitrobenze Sulfonic Acid In Rats", <i>European Journal Pharmacology</i> 431:91-102 (2001)

EXAMINER /Catherine Hibbert/ DATE CONSIDERED 05/22/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 08830-0344US1	SERIAL NO. Not Yet Known
INFORMATION DISCLOSURE STATEMENT				International No.: PCT/IB2003/006404	
				APPLICANT: Koen Vandenbroeck et al.	
				FILING DATE Herewith	GROUP 1636 Not Yet Known

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/C.H./	AA	5,972,986	10/26/1999	Seibert et al.	514	406	
/C.H./	AB	2002/0119193	8/29/2002	Le et al.	424	465	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <u>YES</u> <u>NO</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/C.H./	AC	Dunlop et al., "Inducible Expression And Pharmacology Of The Human Excitatory Amino Acid Transporter 2 Subtype Of L-Glutamate Transporter", <i>British Journal Of Pharmacology</i> 128:1485-1490 (1999)
/C.H./	AD	Graham et al., "Ecdysone-Controlled Expression Of Transgenes", <i>Expert Opinion On Biological Therapy</i> 2:525-535 (2002)
/C.H./	AE	Martens et al., "Protein Disulfide Isomerase-Mediated Cell-Free Assembly Of Recombinant Interleukin-12 p40 Homodimers", <i>European Journal Of Biochemistry</i> 267:6679-6683 (2000)
/C.H./	AF	Nagy et al., "Inducible Expression And Pharmacology Of Recombinant NMDA Receptors, Composed Of Rat NR1/NR2B Subunits", <i>Neurochemistry International</i> 43:19-29 (2003)
/C.H./	AG	Davies et al., "Clinical Pharmacokinetics And Pharmacodynamics Of Celecoxib", <i>Clinical Pharmacokinetics</i> 38:225-242 (2000)
/C.H./	AH	Chen et al., "Selective Inhibition Of COX-2 Is Beneficial To Mice Infected Intranasally With VSV", <i>Prostaglandins And Other Lipid Mediators</i> 67:143-155 (2002)
/C.H./	AI	Cuzzocrea et al., "Celecoxib, A Selective Cyclo-Oxygenase-2 Inhibitor Reduces The Severity Of Experimental Colitis Induced By Dinitrobenze Sulfonic Acid In Rats", <i>European Journal Pharmacology</i> 431:91-102 (2001)

EXAMINER

/Catherine Hibbert/

DATE CONSIDERED

05/22/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.